Swiss National Bank Passage Bio, Inc. Transaction History

Swiss National Bank

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$1.63 - $3.46 $96,985 - $205,870	-59,500 Closed	0 $0
Q4 2021 Feb 08, 2022	BUY	$6.24 - $10.2 $36,192 - $59,159	5,800 Added 10.8%	59,500 $378,000
Q1 2021 May 07, 2021	BUY	$16.24 - $29.83 $454,719 - $835,240	28,000 Added 108.95%	53,700 $939,000
Q4 2020 Feb 05, 2021	SELL	$14.28 - $29.73 $71,400 - $148,650	-5,000 Reduced 16.29%	25,700 $657,000
Q2 2020 Aug 05, 2020	BUY	$14.59 - $36.07 $447,913 - $1.11 Million	30,700 New	30,700 $839,000

37.7M

10.5K

Ticker PASG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,463,200
Market Cap $20.7M
Description
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.